Targeting GPR119 for the potential treatment of type 2 diabetes mellitus.
G protein-coupled receptor 119 (GPR119) was initially identified as an orphan receptor through mining the human genome database. In 2005, GPR119 was deorphanized and shown to be a receptor for fatty acid metabolites, including some phospholipids and fatty acid amide derivatives. GPR119 regulates various physiological processes that improve glucose homeostasis, including glucose-dependent insulin secretion from pancreatic β-cells, gastrointestinal incretin hormone secretion, appetite control, epithelial electrolyte homeostasis, gastric emptying, and β-cell proliferation and cytoprotection. Therefore, GPR119, the sensing receptor for fatty acid metabolites, represents a novel drug target for the treatment of type 2 diabetes mellitus.